Next Article in Journal
Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region
Previous Article in Journal
Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1344088
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment

by
Mondher Toumi
1,*,
Anastasiia Motrunich
2,
Aurélie Millier
2,
Cécile Rémuzat
2,
Christos Chouaid
3,4,
Bruno Falissard
5 and
Samuel Aballéa
1,2
1
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex EA 3279, France
2
Health Economics and Outcomes Research Department, Creativ-Ceutical, Paris, France
3
Faculté de médecine, INSERM U955 and Université Paris Est (UPEC)UMR U955, Créteil, France
4
Département de Pneumologie et Pathologie Professionnelle, Centre Hospitalier Intercommunal DHU-ATVB, Créteil, France
5
INSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1344088; https://doi.org/10.1080/20016689.2017.1344088
Submission received: 16 May 2017 / Revised: 1 January 2017 / Accepted: 13 June 2017 / Published: 16 July 2017

Abstract

Background: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices. Objective: to review the reports published by CEESP, analyse deviations from the guidelines, and discuss their implications for the pricing and reimbursement process. Study design: CEESP reports published until January 2017 were reviewed, and deviations from the guidelines were extracted. The frequency of deviations was described by type of methodological concern (minor, important or major). Results: In 19 reports, we identified 243 methodological concerns, most often concerning modelling, measurement and valuation of health states and results presentation and sensitivity analyses; nearly 63% were minor, 33% were important and 4.5% were major. All reports included minor methodological concerns, and 17 (89%) included at least one important and/or major methodological concern. Global major methodological concerns completely invalidated the analysis in seven dossiers (37%). Conclusion: The CEESP submission dossiers fail to adhere to the guidelines, potentially invalidating the health economics analysis and resulting in pricing negotiations. As these negotiations tend to be unfavourable for the manufacturer, the industry should strive to improve the quality of the analyses submitted to CEESP.
Keywords: health technology assessment; HTA; HAS; CEESP; efficiency opinion; pricing; health economics analysis; HAS guidelines health technology assessment; HTA; HAS; CEESP; efficiency opinion; pricing; health economics analysis; HAS guidelines

Share and Cite

MDPI and ACS Style

Toumi, M.; Motrunich, A.; Millier, A.; Rémuzat, C.; Chouaid, C.; Falissard, B.; Aballéa, S. Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment. J. Mark. Access Health Policy 2017, 5, 1344088. https://doi.org/10.1080/20016689.2017.1344088

AMA Style

Toumi M, Motrunich A, Millier A, Rémuzat C, Chouaid C, Falissard B, Aballéa S. Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment. Journal of Market Access & Health Policy. 2017; 5(1):1344088. https://doi.org/10.1080/20016689.2017.1344088

Chicago/Turabian Style

Toumi, Mondher, Anastasiia Motrunich, Aurélie Millier, Cécile Rémuzat, Christos Chouaid, Bruno Falissard, and Samuel Aballéa. 2017. "Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment" Journal of Market Access & Health Policy 5, no. 1: 1344088. https://doi.org/10.1080/20016689.2017.1344088

APA Style

Toumi, M., Motrunich, A., Millier, A., Rémuzat, C., Chouaid, C., Falissard, B., & Aballéa, S. (2017). Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment. Journal of Market Access & Health Policy, 5(1), 1344088. https://doi.org/10.1080/20016689.2017.1344088

Article Metrics

Back to TopTop